Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
  • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
  • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
  • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/65—Tetracyclines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
  • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
  • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
  • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• liposomes and lipid complexes supply a prolonged therapeutic effect of drug in the lung. These technologies also provide the drag with sustained activities, and the ability to target and enhance the uptake of the drug into sites of disease.
• NTM non-tuberculous mycobacterium
• PNTM pulmonary nontuberculous mycobacterial disease
• MAC Mycobacterium avium complex
• pulmonary NTM infections can be serious or life threatening. Available therapies may be poorly tolerated, and may have significant adverse events.
• the present invention addresses this and other needs by providing methods for treating pulmonary NTM infections in patients in need thereof,
• the present invention provides methods for treating or providing prophylaxis against a nontubercuious mycobacterial (NTM) infection (pulmonary infection caused or due to one or more nontubercuious mycobacteria), via inhalation admin stration of an effective amount of a composition comprising a liposomal complexed aminoglycoside, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
• NTM nontubercuious mycobacterial
• the patient in need of treatment in one embodiment, is a cystic fibrosis patient, a bronchiectasis patient, suffers from asthma or suffers from chronic obstructive pulmonary disorder (COPD).
• COPD chronic obstructive pulmonary disorder
• the NTM infection is a pulmonary NTM infection selected from an M. avium, M. avium subsp. hominissuis (MAH), M. abscessus, M. chelonae, M. boUetii, M. kansasii, M. ulcerans, M. avium, M. avium complex (MAC) ( avium and M. intracellulare), M. conspicuum, M. kansasii, M. peregriniun, M. immunogenum, M. xenopi, M. marinum, M. malmoense, M. marinum, M. mucogenicum, M. nonchromogenicum, M.
• M. avium subsp. hominissuis MAH
• M. abscessus M. chelonae
• M. boUetii M. kansasii
• M. ulcerans M. avium
• the NTM infection is an M, avium complex (MAC) (M. avium and M. intracellulare) infection.
• the NTM infection is a pulmonary recalcitrant NTM infection.
• the composition comprising the liposomal complexed aminoglycoside is a dispersion (e.g., a liposomal solution or suspension).
• the liposomal portion of the composition comprises a lipid component that includes electrically neutral lipids.
• the electrically neutral lipids comprise a phosphatidylcholine and a sterol (e.g., dipalmitoylphospbatidylcholme and cholesterol), in a further embodiment, the aminoglycoside is amikacin or a pharmaceutically acceptable salt thereof. In even a further embodiment, the aminoglycoside is amikacin sulfate.
• the method for treating or providing prophylaxis against an NTM infection comprises administering an aerosolized pharmaceutical composition to the lungs of the patient in need thereof; wherein the aerosolized pharmaceutical composition comprises a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and the lipid component of the liposome consists of electrically neutral lipids.
• the electrically neutral lipids comprise a phosphatidylcholine and a sterol (e.g., dipalmitoylphosphatidylcholine and cholesterol).
• the aminoglycoside is amikacin or a pharmaceutically acceptable salt thereof.
• the aminoglycoside is amikacin sulfate.
• the methods provided herein result in a change from baseline on the semiquantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.
• the method provided herein results in the patient having an NTM culture conversion to negative after an administration period.
• the aminoglycoside or pharmaceutically acceptable salt thereof is amikacin, apramycin, arbekacin, astromicin, capreomycin, dibekacin, framycetin, gentamicin, hygromycin B, isepamicin, kanamycm, neomycin, netilmicin, paromomycin, rhodestreptomycin, ribostamycin, sisomicin, spectinomycin, streptomycin, tobramycin, verdamicin, a pharmaceutically acceptable salt thereof, or a combination thereof.
• the aminoglycoside is amikacin.
• the aminoglycoside is selected from an aminoglycoside set forth in Table 1, below, a pharmaceutically acceptable salt thereof, or a combination thereof.
• compositions provided herein in one embodiment are dispersions of liposomes (i.e., liposomal dispersions or aqueous liposomal dispersions which can be either liposomal solutions or liposomal suspensions).
• the lipid component of the liposomes consists essentially of one or more electrically neutral lipids.
• the electrically neutral lipid comprises a phospholipid and a sterol.
• the phospholipid is dipalmitoyiphosphatidylchoiine (DPPC) and the sterol is cholesterol
• the lipid to ammoglycoside weight ratio in the ammoglycoside pharmaceutical composition is about 2: 1, about 2: 1 or less, about 1 : 1, about 1 :1 or less, about 0.75: 1 or less, or about 0.7: 1.
• the lipid to ammoglycoside weight ratio in the composition is from about 0.10: 1 to about 1 .25: 1 , from about 0, 10: 1 to about 1.0: 1, from about 0.25:1 to about 1 .25:1, from about 0.5: 1 to about 1 : 1.
• the methods provided herein comprise administration of the liposomal aminoglycoside composition via nebulization or aerosol zafion.
• the method in this embodiment therefore entails generation of an aerosolized aminoglycoside composition.
• the aerosolized composition upon nebulization, has an aerosol droplet size of about 1 ⁇ to about 3.8 ,um, about 1.0 ⁇ to 4.8 ⁇ , about 3.8 ⁇ to about 4.8 ⁇ , or about 4.0 ⁇ to about 4.5 ⁇ .
• the aminoglycoside is amikacin.
• the amikacin is amikacin sulfate.
• about 70% to about 100% of the ammoglycoside present in the composition is liposomal complexed, e.g., encapsulated in a plurality of liposomes, prior to administration to the patient in need of treatment.
• the aminoglycoside is selected from an aminoglycoside provided in Table 1.
• the aminoglycoside is an amikacin (e.g., as amikacin sulfate), in even a further embodiment, about 80% to about 100% of the amikacin is liposomal complexed, or about 80% to about 100% of the amikacin is encapsulated in a plurality of liposomes, prior to administration to the patient in need of treatment.
• prior to administration to the patient in need of treatment i.e., prior to nebulization
• about 80% to about 100%,, about 80%» to about 99%, about 90% to about 100%, 90% to about 99%, or about 95% to about 99% of the aminoglycoside present in the composition is liposomal complexed.
• the percent liposomal complexed (also referred to herein as "liposomal associated") aminoglycoside post-nebulization is from about 50% to about 80%, from about 50% to about 75%, from about 50% to about 70%, from about 55% to about 75%, or from about 60% to about 70%.
• the aminoglycoside is selected from an aminoglycoside provided in Table 1.
• the aminoglycoside is amikacin.
• the amikacin is amikacin sulfate.
• the aerosolized composition (i.e., post nebulization) comprises from about 65% to about 75% liposomal complexed aminoglycoside and from about 25%> to about 35% free aminoglycoside.
• the aminoglycoside is amikacin.
• the amikacin is amikacin sulfate.
• the pulmonary infection treated by the methods provided herein is a Mycobacterium abscessus pulmonary infection or a Mycobacterium avium, complex pulmonary infection.
• the patient is a cystic fibrosis patient, a bronchiectasis patient, an asthma patient or a COPD patient.
• a patient with cystic fibrosis is treated for a pulmonary infection with one of the compositions or systems provided herein, in a further embodiment, the pulmonary infection is caused by Mycobacterium abscessus or Mycobacterium avium complex.
• the concentration of the aminoglycoside in the liposomal aminoglycoside composition is about 50 mg/mL or greater. In a further embodiment, the concentration of the aminoglycoside in the liposomal complexed aminoglycoside is about 60 mg/mL or greater. In a further embodiment, the concentration of the aminoglycoside in the liposomal complexed aminoglycoside is about 70 mg/mL or greater, for example about 70 mg/mL to about 75 mg/mL. In a further embodiment, the aminoglycoside is selected from an aminoglycoside provided in Table 1 . In even a further embodiment, the aminoglycoside is amikacin (e.g., amikacin sulfate).
• amikacin e.g., amikacin sulfate
• Figure i shows the study design for a randomized, double-blind, placebo controlled study of liposomal complexed amikacin in patients with recalcitrant nontuberculous mycobacterial (NTM) lung infection, described in Example 1.
• Figure 2 shows the patient distribution for the randomized, double-blind, placebo controlled study of liposomal complexed amikacin in patients with recalcitrant nontuberculous mycobacterial lung infection, described in Example 1.
• Figure 3 shows the number of patients in each ' NTM treatment group.
• Figure 4 shows the log scale (LS) mean change from baseline on the full semi quantitative scale for mycobacterial culture for the modified intent to treat patient (mITT) population as a function of study day for both the double-blind phase and the open-label phase of the study set forth in Example 1 .
• Figure 5 is a bar graph showing the proportion of patients with NTM culture conversion to negative at various time points during the randomized, double-blind, placebo controlled study (modified intent to treat population).
• Figure 5 (bottom) is a bar graph showing the proportion of MAC patients with NTM culture conversion to negative at various time points.
• Figure 6 shows patients with at least 1 NTM culture negative result at various time points during the randomized, double-blind, placebo controlled study.
• Figure 7 (top) is a graph showing the change from baseline in the six-minute walk test at day 84 and day 168 (mITT population) and Figure 7 (bottom) is a graph of the mean change from baseline in distance walked (meters) in the 6MWT in patients receiving LAI vs. placebo at day 84 (last observation carried forward, modified intent to treat population).
• Figure 8 (top) is a graph showing the average meters walked in the six-minute walk test at day 84 and day 168 (ail patients).
• Figure 8 (bottom) is a graph showing the mean change from baseline to Days 84 and 168 in distance walked (meters) in the 6MWT in patients with culture conversion to negative (>3 negative cultures) vs. those without culture conversion to negative (last observation carried forward- modified intent to treat population).
• Figure 9 shows the study design for a randomized, placebo controlled study of liposomal encapsulated amikacin (ARJKAYCE or LAI) in patients with Non-Cystic Fibrosis (Non-CF) M. avium complex (MAC) lung infection, described in Example 2.
• ARJKAYCE or LAI liposomal encapsulated amikacin
• Non-CF Non-Cystic Fibrosis
• MAC avium complex
• the invention described herein is directed, in part, to methods for treating a pulmonary infection in a patient in need thereof, e.g., administering an aminoglycoside pharmaceutical composition to the lungs of the patient, for example, via nebulization.
• the term "treating" includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in the subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition (i.e., arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); and/or (3) relieving the condition (i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms).
• the benefit to a subject to be treated is either statistically significant or at least perceptible to the subject or to the physician.
• “Prophylaxis,” as used herein, can mean complete prevention of an infection or disease, or prevention of the development of symptoms of that infection or disease; a delay in the onset of an infection or disease or its symptoms; or a decrease in the severity of a subsequently developed infection or disease or its symptoms.
• antibacterial is art-recognized and refers to the ability of the compounds of the present invention to prevent, inhibit or destroy the growth of microbes of bacteria. Examples of bacteria are provided above.
• antimicrobial is art-recognized and refers to the ability of the aminoglycoside compounds of the present invention to prevent, inhibit, delay or destroy the growth of microbes such as bacteria, fungi, protozoa and viruses.
• Effective amount means an amount of an aminoglycoside (e.g., amikacin) used in the present invention sufficient to result in the desired therapeutic response.
• the effective amount of the composition provided herein comprises both free and liposomal complexed aminoglycoside.
• the liposomal complexed aminoglycoside in one embodiment, comprises aminoglycoside encapsulated in a liposome, or complexed with a liposome, or a combination thereof.
• Liposomal dispersion refers to a solution or suspension comprising a plurality of liposomes.
• aerosol is a gaseous suspension of liquid particles.
• the aerosol provided herein comprises particles of the liposomal dispersion.
• a "nebulizer” or an “aerosol generator” is a device that converts a liquid into an aerosol of a size that can be inhaled into the respiratory tract.
• Pneumonic, ultrasonic, electronic nebulizers e.g., passive electronic mesh nebulizers, active electronic mesh nebulizers and vibrating mesh nebulizers are amenable for use with the invention if the particular nebulizer emits an aerosol with the required properties, and at the required output rate.
• the process of pneumatically converting a bulk liquid into small droplets is called atomization.
• the operation of a pneumatic nebulizer requires a pressurized gas supply as the driving force for liquid atomization.
• Ultrasonic nebulizers use electricity introduced by a piezoelectric element in the liquid reservoir to convert, a liquid into respirable droplets.
• Various types of nebulizers are described in Respiratory Care, Vol, 45, No. 6, pp. 609-622 (2000), the disclosure of which is incorporated herein by reference in its entirety.
• the terms “nebulizer” and “aerosol generator” are used interchangeably throughout the specification, "Inhalation device,” “inhalation system” and “atomizer” are also used in the literature interchangeably with the terms “nebulizer” and "aerosol generator.”
• Mass median diameter is determined by laser diffraction or impactor measurements, and is the average particle diameter by mass.
• Mass median aerodynamic diameter or “MMAD” is normalized regarding the aerodynamic separation of aqua aerosol droplets and is determined impactor measurements, e.g., the Anderson Cascade Impactor (ACI) or the Next Generation Impactor (NGI).
• the gas flow rate in one embodiment, is 28 Liter per minute by the Anderson Cascade Impactor (ACI) and 15 Liter per minute by the Next Generation Impactor (NGI).
• Geometric standard deviation or “GSD” is a measure of the spread of an aerodynamic particle size distribution.
• Non tuberculous mycobacteria are organisms found in the soil and water that can cause serious lung disease in susceptible individuals, for which there are currently limited effective treatments and no approved therapies.
• the prevalence of NT disease is reported to be increasing, and according to reports from the American Thoracic Society is believed to be greater than that of tuberculosis in the U.S.
• epidemiological studies show that presence of NTM infection is increasing in developing countries, perhaps because of the implementation of tap water. Women with characteristic phenotype are believed to be at higher risk of acquiring NTM infection along with patients with defects on cystic fibrosis transmembrane conductance regulators.
• high risk groups with NTM lung disease for increased morbidity and mortality are those with cavitary lesions, low BMI, advanced age, and a high comorbidity index.
• NTM lung disease is often a chronic condition that can lead to progressive inflammation and lung damage, and is characterized by bronchiectasis and cavitary disease, NTM. infections often require lengthy hospital stays for medical management. Treatment usually involves multi-drag regimens that can be poorly tolerated and have limited effectiveness, especially in patients with severe disease or in those who have failed prior treatment attempts. According to a company-sponsored patient chart study conducted by Clarity Pharma Research, approximately 50,000 patients suffering from NTM lung disease visited physician offices in the U.S. during 201 1 .
• NTM nontuberculous mycobacteria
• the present invention provides methods for treating a pulmonary nontuberculous mycobacterial (NTM) infection in a patient in need thereof.
• the method in one embodiment comprises administration to the patient a composition comprising a liposomal complexed aminoglycoside, or a pharmaceutically acceptable salt thereof for an administration period.
• the liposomal complexed aminoglycoside in one embodiment, comprises the aminoglycoside or pharmaceutically acceptable salt thereof encapsulated in a plurality of liposomes.
• the plurality of liposomes in one embodiment, include a lipid component that consists of neutral lipids.
• the neutral lipids comprise a phospholipid and a sterol.
• the phospholipid is a phosphatidylcholine.
• the phosphatidylcholine is dipalmitoylphosphatidylcholme (DPPC).
• DPPC dipalmitoylphosphatidylcholme
• the sterol is cholesterol.
• the nontuberculous mycobacterial lung infection is a recalcitrant nontuberculous mycobacterial lung infection.
• the patient in one embodiment, exhibits an increased number of meters walked in the 6MWT, as compared to prior to treatment and/or an NTM culture conversion to negative, during the administration period or after the administration period.
• the therapeutic response can be any response that a user (e.g., a clinician) will recognize as an effective response to the therapy.
• the therapeutic response will generally be a reduction, inhibition, delay or prevention in growth of or reproduction of one or more NTM, or the killing of one or more NTM.
• a therapeutic response may also be reflected in an improvement in pulmonary function, for example forced expiratory volume in one second (FEVj).
• FEVj forced expiratory volume in one second
• the therapeutic response is measured as the change from baseline on the full semi quantitative scale for mycobacterial culture or an improvement in the distance walked in the 6 minute walk test (6MWT). It is further within the skill of one of ordinary skill in the art to determine appropriate treatment duration, appropriate doses, and any potential combination treatments, based upon an evaluation of therapeutic response.
• the NTM lung infection treatable by the methods and compositions described herein is M. avium, M. avium subsp. hominissuis (MAH), M. abscessus, M. chelonae, M. holletii, M. kansasii, M. ulcerans, M. avium, M. avium complex (MAC) (M. avium and M. intracellulare), M. conspicuum, M. kansasii, M. peregrinum, M. immunogenum, M. xenopi, M. marinum, M. malmoense, M. marinum, mucogenicum, M. nonchromogenicum, M.
• MAH M. avium subsp. hominissuis
• M. abscessus M. chelonae
• M. holletii M. kansasii
• M. ulcerans M. avium
• M. avium complex (MAC) M
• the nontuberculous mycobacterial lung infection is M. avium complex (MAC) (M. avium and M.
• M. abscessus or M. avium In a further embodiment, the M. avium infection is M, avium subsp. hominissuis.
• the nontuberculous mycobacterial lung infection is M. avium complex (MAC) (M. avium and M. intracellulare).
• the NTM lung infection is a recalcitrant nontuberculous mycobacterial lung infection.
• compositions and systems described herein are used to treat an infection caused by a nontuberculous mycobacteriurn (NTM).
• NTM nontuberculous mycobacteriurn
• the compositions and systems described herein are used to treat an infection caused by Mycobacterium abscessus, Mycobacterium avium or M. avium complex.
• the Mycobacterium avium infection is Mycobacterium avium subsp. hominissuis.
• a patient is treated for a Mycobacterium abscessus, M. kansasii, M. abscessus, M. fortuitum, Mycobacterium avium or a M. avium complex (MAC) lung infection via inhalation delivery of a liposomal aminoglycoside composition.
• the aminoglycos de is amikacin sulfate and is administered once per day for in a single dosing session.
• the NTM lung infection is MAC.
• the NTM lung infection in one embodiment, is associated with cavitary lesions.
• the NTM lung infection is a nodular infection.
• the NTM lung infection is a nodular infection with minimal cavitary lesions.
• the aminoglycoside or pharmaceutically acceptable salt thereof, administered via the methods described herein is selected from amikacin, apramycin, arbekacin, astromicin, capreomycin, dibekacin, framycetin, gentamicin, hygromycin B, isepamicin, kanamycin, neomycin, netilmicin, paromomycin, rhodestreptornycin, ribostamycin, sisomicin, spectinomycin, streptomycin, tobramycin, verdamicin, or a pharmaceutically acceptable salt thereof.
• the aminoglycoside is amikacin.
• the amikacin is amikacin sulfate.
• the aminoglycoside is selected from an aminoglycoside set forth in Table 2, below, a pharmaceutically acceptable salt thereof, or a combination thereof.
• a a pharmaceutically acceptable salt such as a sulfate salt of one or more of the aminoglycosides set forth in Table 2 ca be formulated in a liposomal composition and administered to a patient in need of NTM treatment, e.g., via pulmonary delivery by a nebulizer.
• a pharmaceutical composition comprises a combination of aminoglycosides, or pharmaceutically acceptable salts thereof, e.g., a combination of two or more aminoglycosides, or pharmaceutically acceptable salts thereof as set forth in Table 2.
• the composition comprising the liposomal complexed aminoglycoside comprises from 1 to about 5 aminoglycosides, or pharmaceutically acceptable salts thereof.
• the composition comprising the liposomal complexed aminoglycoside comprises at least 1 , at least 2, at least 3, at least 4, at least 5, or at least 6, of
• a pharmaceutical composition comprises between 1 and 4 aminoglycosides, or pharmaceutically acceptable salts thereof.
• the combination comprises amikacin, e.g., as amikacin sulfate.
• the aminoglycoside is an aminoglycoside free base, or its salt, solvate, or other non-covalent derivative.
• the aminoglycoside is amikacin.
• suitable aminoglycosides used in the drug compositions of the present invention are pharmaceutically acceptable addition salts and complexes of drugs.
• the present invention comprises each unique racemic compound, as well as each unique nonracemic compound.
• both the cis (Z) and trans (E) isomers are within the scope of this invention.
• each tautomeric form is contemplated as being included within the invention.
• Amikacin in one embodiment, is present in the pharmaceutical composition as amikacin base, or amikacin salt, for example, amikacin sulfate or amikacin disulfate. In one embodiment, a combination of one or more of the above aminoglycosides is used in the compositions, systems and methods described herein,
• the present invention provides in one aspect, a method for treating or providing prophylaxis against a pulmonary NTM infection. Treatment is achieved via delivery of a composition comprising a liposomal aminoglycoside composition by inhalation via nebulization of the composition.
• the composition comprises an aminoglycoside encapsulated in a plurality of liposomes, e.g., an aminoglycoside selected from one or more of the aminoglycosides of Tables 1 and/or 2, or a pharmaceutically acceptable salt thereof.
• the pharmaceutical composition is a liposomal dispersion comprising an aminoglycoside complexed to a liposome, e.g., an aminoglycoside encapsulated in a plurality of liposomes.
• the pharmaceutical composition is a dispersion comprising a "liposomal complexed aminoglycoside” or an "aminoglycoside encapsulated in a liposome.”
• a “liposomal complexed aminoglycoside” includes embodiments where the aminoglycoside (or combination of aminoglycosides) is encapsulated in a liposome, and includes any form of aminoglycoside composition where at least about 1% by weight of the aminoglycoside is associated with the liposome either as part of a complex with a liposome, or as a liposome where the aminoglycoside may be in the aqueous phase or the hydrophobic biiayer phase or at the interfacial headgroup region of the liposomal bilayer.
• the lipid component of the liposome or plurality of liposomes comprises electrically neutral lipids, positively charged lipids, negatively charged lipids, or a combination thereof.
• the lipid component comprises electrically neutral lipids.
• the lipid component consists essentially of electrically neutral lipids.
• the electrically neutral lipids comprise a sterol and a phospholipid.
• the sterol is cholesterol and the phospholipid is a neutral phosphatidylcholine.
• the phosphatidylcholine is dipalmitoylphosphatidylcholine (DPPC).
• liposomal complexed aminoglycoside embodiments include embodiments where the aminoglycoside or phannaceutically acceptable salt thereof is encapsulated in a plurality of liposomes.
• the liposomal complexed aminoglycoside describes any composition, solution or suspension where at least about 1% by weight of the aminoglycoside is associated with the lipid either as part of a complex with the liposome, or as a liposome where the aminoglycoside may be in the aqueous phase or the hydrophobic bilayer phase or at the interfacial headgroup region of the liposomal bilayer.
• association in one embodiment, is measured by separation through a filter where lipid and lipid-associated drug is retained (i.e., in the retentate) and free drug is in the filtrate.
• the methods provided herein comprise administering to a patient in need thereof a composition comprising an aminoglycoside or phannaceutically acceptable salt thereof encapsulated in a plurality of liposomes.
• One or more lipids can be used to form the plurality of liposomes.
• the one or more lipids is synthetic, semi-synthetic or a naturally-occurring lipid, including a phospholipid, tocopherol, sterol, fatty acid, negatively- charged lipid, cationic lipid or a combination thereof.
• the lipid component of the plurality of liposomes consists of electrically neutral lipids.
• the lipid component comprises DPPC and cholesterol.
• the phospholipid is present in the plurality of liposomes.
• the phospholipid in one embodiment, is electrically net neutral .
• the phospholipid is a phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylethanol amine (PE), and phosphatidic acid (PA); the soya counterparts, soy phosphatidylcholine (SPC); SPG, SPS, SPI, SPE, and SPA; the hydrogenated egg and soya counterparts (e.g., HEPC, HSPC), phospholipids made up of ester linkages of fatty acids in the 2 and 3 of glycerol positions containing chains of 12 to 26 carbon atoms and different head groups in the 1 position of glycerol that include choline, glycerol, inositol
• PC phosphatidylcho
• the lipid component of the plurality of liposomes includes dipalmitoylphosphatidylcholme (DPPC), a major constituent of naturally-occurring lung surfactant.
• DPPC dipalmitoylphosphatidylcholme
• the lipid component of the plurality of liposomes comprises DPPC and cholesterol, or consists essentially of DPPC and cholesterol, or consists of DPPC and cholesterol.
• the DPPC and cholesterol have a mole ratio in the range of from about 19: 1 to about 1 : 1 , or about 9: 1 to about 1 : 1 , or about 4: 1 to about 1 : 1 , or about 2: 1 to about 1 : 1 , or about 1.86: 1 to about 1 : 1.
• the DPPC and cholesterol have a mole ratio of about 2: 1 or about 1 : 1.
• lipids for use with the methods and compositions described herein include, but are not limited to, dimyristoylphosphatidycboiine (DMPC), dimyristoylphosphatidylglyceroi (DMPG), dipalmitoylphosphatidcholine (DPPC ).
• DMPC dimyristoylphosphatidycboiine
• DMPG dimyristoylphosphatidylglyceroi
• DPPC dipalmitoylphosphatidcholine
• dipalmitoylphosphatidylglycerol DPPG
• distearoylphosphatidylcholine DSPC
• distearoylphosphatidylglycerol DSPG
• dioleylphosphatidyl-ethanolamine DOPE
• mixed phospholipids such as palmitoylstearoylphosphatidyl-choline (PSPC)
• PSPC palmitoylstearoylphosphatidyl-choline
• MOPE mono-oleoyl-phosphatidylethanolamine
• the lipid component of the plurality of liposomes comprises a sterol.
• the at least one lipid component comprises a sterol and a phospholipid, or consists essentially of a sterol and a phospholipid, or consists of a sterol and a phospholipid (e.g., a neutral phosphatidylcholine such as DPPC).
• Sterols for use with the invention include, but are not limited to, cholesterol, esters of cholesterol including cholesterol hemi-suceinate, salts of cholesterol including cholesterol hydrogen sulfate and cholesterol sulfate, ergosterol, esters of ergosterol. including ergosterol hemi-succinate, salts
• the tocopherols can include tocopherols, esters of tocopherols including tocopherol hemi-succmates, salts of tocopherols including tocopherol hydrogen sulfates and tocopherol sulfates.
• the term "sterol compound" includes sterols, tocopherols and the like.
• At least one cationic lipid (positively charged lipid) is provided in the lipid component of the plurality of liposomes, present in the liposomal aminoglycoside compositions described herein, for use in the method of treating an NTM pulmonary infection in a patient in need thereof
• Cationic lipids amendable for use with the present invention include but are not limited to ammonium salts of fatty acids, phospholids and glycerides.
• the fatty acids include fatty acids of carbon chain lengths of 12 to 26 carbon atoms that are either saturated or unsaturated.
• Some specific examples include, but are not limited to, myristyiamme, pal.mitylam.ine, laurylamine and stearylamine, dilauroyl ethylphosphochohne (DLEP), dimyristoyl ethylphosphocholme (DMEP), dipalmitoyl ethylphosphocholme (DPEP) and distearoy 1 ethylphosphocholme (DSEP), N-(2,3-di-(9-(Z)-octadecenyloxy)-prop- 1 -yl- ⁇ , , -trimethylammonium chloride (DOTMA), 1 ,2-bis(oleoyloxy)-3-(irimethylammomo) propane (DGTAP), and combinations thereof.
• DLEP dilauroyl ethylphosphochohne
• DMEP dimyristoyl ethylphosphocholme
• DPEP dipalmitoyl ethylphospho
• At least one anionic lipid is provided in the lipid component of the plurality of liposomes, present in the liposomal aminoglycoside compositions described herein, for use in the method of treating an NTM pulmonary infection in a patient in need thereof.
• the negatively-charged lipids which can be used include phosphatidyl-glycerols (PGs), phosphatidic acids (PAs), phosphatidyiinositols (Pis) and the phosphatidyl serines (PSs). Examples include but are not limited to DMPG, DPPG, DSPG, DMPA, DPP A, DSPA, DMPI, DPPL DSPI, DMPS, DPPS, DSPS and combinations thereof.
• phosphatidylcholines such as DPPC
• aid in the uptake of the aminoglycoside agent by the cells in the lung e.g., the alveolar macrophages
• the negatively charged lipids such as the PGs, PAs, PSs and Pis, in addition to reducing particle aggregation, are thought to play a role in the sustained activity characteristics of the inhalation composition as well as in the transport of the composition across the lung (transcytosis) for systemic uptake.
• the sterol compounds without wishing to be bound by (henry, are thought to affect the release characteristics of the composition.
• Liposomes are completely closed lipid bilayer membranes containing an entrapped aqueous volume. Liposomes may be unilamellar vesicles (possessing a single membrane bilayer) or multilamellar vesicles (onion-like structures characterized by multiple membrane bilayers, each separated from the next by an aqueous layer) or a combination thereof.
• the bilayer is composed of two lipid monolayers having a hydrophobic "tail” region and a hydrophilic "head” region.
• the structure of the membrane bilayer is such that the hydrophobi c (nonpo!ar) "tails" of the lipi d monolayers orient toward the center of the bilayer while the hydrophilic "heads” orient towards the aqueous phase.
• the lipid to aminoglycoside ratio by weight (weight ratios are also referred to herein as "lipid : aminoglycoside”) in the pharmaceutical composition provided herein in one embodiment, is 3:1 or less, 2.5: 1.0 or less, 2: 1 or less, 1.5: 1 or less, 1 : 1 or less or 0.75: 1 or less, in one embodiment, the lipid : aminoglycoside w r eight ratio in the composition provided herein is 0.7: 1.0 or about 0.7: 1.0 by w r eight. in another embodiment, the L:D ratio in liposomes provided herein is 0.75: 1 or less (by weight).
• the lipid : aminoglycoside weight ratio (lipid to aminoglycoside weight ratio) is from about 0.10: 1.0 to about 1.25: 1.0, from about 0.25: 1.0 to about 1 .25: 1.0, from about 0.50: 1.0 to about 1.25: 1.0 or from about 0.6: 1 to about 1 ,25: 1 .0.
• the lipid to aminoglycoside weight ratio is from about 0.1 : 1.0 to about 1 ,0: 1.0, or from about 0.25: 1.0 to about 1.0: 1.0 or about 0.5: 1 to 1 : 1 ,0.
• the lipid to aminoglycoside weight ratio in the composition provided herein in another embodiment is less than 3: 1, less than 2.5: 1 ,0, less than 2,0: 1.0, less than 1.5:1.0, or less than 1.0: 1 ,0. in a further embodiment, the lipid to aminoglycoside weight ratio is about 0,7:1.0 or less or about 0.7: 1.0. In yet another embodiment, the lipid to aminoglycoside weight ratio is from about 0.5: 1 ,0 to about 0.8: 1 .0.
• liposomal entrapment of the aminoglycoside e.g., the aminoglycoside amikacin
• the aminoglycoside amikacin be highly efficient and that the lipid to aminoglycoside weight ratio be at as low a value as possible and/or practical while keeping the liposomes small enough to penetrate patient mucus and biofilms.
• the L aminoglycoside weight ratio in the composition provided herein i.e., the composition comprising an aminoglycoside encapsulated in a plurality of liposomes is 0.7: 1.0, about 0.7:1 ,0 from about 0.5: 1.0 to about 0.8: 1.0 or from about 0.6: 1.0 to about 0.8: 1.0.
• the liposomes provided herein are small enough to effectively penetrate a bacterial biofilm. In even a
• the mean diameter of the plurality of liposomes, as measured by light scattering is from about 200 nm to about 400 nm, or from about 250 nm to about 400 nm, or from about 250 nm to about 300 nm, or from about 200 nm to about 300 nm. In even a further embodiment, the mean diameter of the plurality of liposomes, as measured by light scattering is from about 260 to about 280 nm.
• the liposomal compositions described herein are manufactured by one of the methods set forth in U.S. Patent Application Publication No. 2013/0330400 or U.S. Patent No. 7,718,189, each of which is incorporated by reference in its entirety for all purposes.
• Liposomes can be produced by a variety of methods (see, e.g., Cullis et al. (1987)).
• one or more of the methods described in U.S. Patent Application Publication No. 2008/0089927 are used herein to produce the aminoglycoside encapsulated lipid compositions (liposomal dispersion).
• At least one lipid and an aminoglycoside are mixed with a coacervate (i.e., a separate liquid phase) to form the liposome composition.
• a coacervate i.e., a separate liquid phase
• the coacervate can be formed to prior to mixing with the lipid, during mixing with the lipid or after mixing with the lipid.
• the coacervate can be a coacervate of the active agent
• the liposomal dispersion is formed by dissolving one or more lipids in an organic solvent forming a lipid solution, and the aminoglycoside coacervate forms from mixing an aqueous solution of the aminoglycoside with the lipid solution.
• the organic solvent is ethanol.
• the lipid solution comprises a phospholipid and a sterol, e.g., DPPC and cholesterol.
• liposomes are produces by sonication, extrusion, homogenization, swelling, e lect.ro formation, inverted emulsion or a reverse evaporation method.
• Bangham's procedure J. Mol. Biol. (1965)
• MMVs multilamellar vesicles
• Unilamellar vesicles can be produced from MLVs by a number of techniques, for example, the extrusion techniques of U.S. Patent No. 5,008,050 and U.S. Patent No. 5,059,421.
• Sonication and homogenization cab be so used to produce smaller unilamellar liposomes from larger liposomes (see, for example, Paphadjopoulos et al. (1968); Deamer and Uster (1983); and Chapman et al. (1968)).
• the liposome preparation of Bangham et al. involves suspending phospholipids in an organic solvent which is then evaporated to dryness leaving a phospholipid film on the reaction vessel. Next, an appropriate amount of aqueous phase is added, the 60 mixture is allowed to "swell,” and the resulting liposomes which consist of multilamellar vesicles (MLVs) are dispersed by mechanical means.
• MLVs multilamellar vesicles
• liposomes include those that form reverse-phase evaporation vesicles (REV), U.S. Patent No. 4,235,871.
• REV reverse-phase evaporation vesicles
• Another class of liposomes that may be used is characterized as having substantially equal lamellar solute distribution.
• This class of liposomes is denominated as stable pluriiamellar vesicles (SPLV) as defined in U.S. Patent- No. 4,522,803, and includes monophasic vesicles as described in U.S. Patent No. 4,588,578, and frozen and thawed multilamellar vesicles (FATMLV) as described above.
• SPLV stable pluriiamellar vesicles
• FATMLV frozen and thawed multilamellar vesicles
• a variety of sterols and their water soluble derivatives such as cholesterol hemisuccinate have been used to form liposomes; see, e.g., U.S. Patent No. 4,721,612. Mayhew et al., PCT Publication No. WO 85/00968, described a method for reducing the toxicity of drugs by encapsulating them in liposomes comprising alpha-tocopherol and certain derivatives thereof. Also, a variety of tocopherols and their water soluble derivatives have been used to form liposomes, see PCT Publication No. 87/02219.
• the pharmaceutical composition in one embodiment, pre-nehulization, comprises liposomes with a mean diameter, that is measured by a light scattering method, of approximately 0.01 microns to approximately 3.0 microns, for example, in the range about 0.2 to about 1 .0 microns.
• the mean diameter of the liposomes in the composition is about 200 nm to about 300 nm, about 210 nm to about 290 nm, about 220 nm to about 280 nm, about 230 nm to about 280 nm, about 240 nm to about 280 nm, about 250 nm to about 280 nm or about 260 nm to about 280 nm.
• the sustained activity profile of the liposomal product can be regulated by the nature of the lipid membrane and by inclusion of other exeipients in the composition.
• the method described herein comprises administering a liposomal compiexed aminoglycoside composition, e.g., a liposomal complexed amikacin (e.g., amikacin sulfate) composition to a patient in need thereof via inhalation, for example, via a nebulizer.
• a liposomal compiexed aminoglycoside composition e.g., a liposomal complexed amikacin (e.g., amikacin sulfate) composition
• the amount of aminoglycoside provided in the composition is about 450 mg, about 500 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg or about 610 mg.
• the amount of aminoglycoside provided in the composition is from about 500 mg to about 600 mg, or from about 500 mg to about 650 mg, or from about 525 mg to about 625 mg, or from about 550 mg to about 600 mg. In one embodiment, the amount of aminoglycoside administered to the subject is about 560 mg and is provided in an 8 mL composition. In one embodiment, the amount of aminoglycoside administered to the subject is about 590 mg and is provided in an 8 mL composition. In one embodiment, the amount of aminoglycoside administered to the subject is about 600 mg and is provided in an 8 mL composition.
• the aminoglycoside is amikacin and the amount of amikacin provided in the composition is about 450 mg, about 500 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg or about 610 mg. In another embodiment, the aminoglycoside is amikacin and the amount of amikacin provided in the composition is from about 500 mg to about 650 mg, or from about 525 mg to about 625 mg, or from about 550 mg to about 600 mg. In one embodiment, the aminoglycoside is amikacin and the amount of amikacin administered to the subject is about 560 mg, and is provided in an 8 mL composition.
• the aminoglycoside is amikacin and the amount of amikacin administered to the subject is about 590 mg, and is provided in an 8 mL composition. In one embodiment, the aminoglycoside is amikacin and the amount of aminoglycoside administered to the subject is about 600 mg and is provided in an 8 mL composition.
• the methods described herein are carried out via the use of a system comprising a liposomal complexed aminoglycoside composition, for example, a liposomal encapsulated amikacin composition (e.g., amikacin sulfate) and a nebulizer.
• a liposomal encapsulated amikacin composition e.g., amikacin sulfate
• the liposomal aminoglycoside composition provided herein comprises about 60 mg/mL aminoglycoside, about 65 mg/mL aminoglycoside, about 70 mg/mL aminoglycoside, about 75 mg/mL. aminoglycoside, about 80 mg/mL aminoglycoside, about 85 mg/mL aminoglycoside, or about 90 mg/mL aminoglycoside.
• the aminoglycoside is amikacin, for example, as amikacin sulfate.
• the liposomal aminoglycoside composition is administered to a patient in need thereof once per day in a single dosing session.
• the composition is administered as an aerosol via a nebulizer.
• the method comprises administering to a patient in need thereof one of the aminoglycoside compositions described herein ever ⁇ ' other day or even' three days.
• the method comprises administering to a patient in need thereof one of the aminoglycoside compositions described herein twice per day.
• the methods provided herein comprise administering to a patient in need thereof one of the compositions described herein (e.g., via a nebulizer) for an administration period comprising at least one 1 month, 2 months, 3 months, 4 months, 5 months or 6 months.
• an administration period is followed by a period where no composition is administered (referred to as "off period"), which is followed by another admin stration period.
• the off period in one embodiment is about 1 month, about 2 months, about 3 months, about four months, about five months or about 6 months,
• the administration period is from about 15 days to about 400 days, e.g., from about 45 days to about 300 days, or from about 45 days to about 270 days, or from about 80 days to about 200 days.
• the administration period comprises administration of the composition to a patient in need thereof in a once daily dosing session.
• the NTM treatment method described herein comprises administration of a liposomal complexed aminoglycoside composition to a patient in need thereof via a once daily dosing session for an administration period.
• the administration period is from about 15 to about 275 days, or from about 20 to about 235 days, or from about 28 days to about 150 days.
• the methods provided herein comprise administering to a patient in need thereof an aminoglycoside composition once per day in a single dosing session for an administration period of from about 15 to about 300 days, or from about 15 to about 250 days, or from about 15 to about 200 days, or from about 15 to about 150 days, or from about 15 to about 125 days or from about 15 to about 100 days.
• the administration period is from about 50 days to about 200 days.
• the patient in need thereof is administered the aminoglycoside composition via nebulization, and about 500 mg to about 1000 rag aminoglycoside is administered daily in a single dosing session, for example, about 500 mg aminoglycoside to about 700 mg aminoglycoside (e.g., about 590 mg aminoglycoside).
• an administration period is followed by an off period from about 15 to about 200 days, for example, from about 15 days to about 150 days, or from about 15 days to about 75 days, from about 15 days to about 35 days, or from about 20 days to about 35 days, or from about 25 days to about 75 days, or from about 35 days to about 75 days or from about 45 days to about 75 days.
• the off period is about 28 days or about 56 days.
• the off period is about 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59 or 60 days, while in other embodiments, the off period is about 56 days.
• the patient in need thereof is administered the liposomal compiexed aminoglycoside composition in a treatment cycle comprising an administration period and an off period.
• the treatment cycle is implemented at least once.
• the treatment cycle is repeated at least twice, for example, two, three, four, five, six, seven, eight, nine or ten times.
• the treatment cycle is repeated at least three times, for example, at least three, at least four, at least five or at least six times.
• the system provided herein comprises an about 8 ml, liposomal amikacin composition and a nebulizer.
• the density of the liposomal amikacin composition is about 1 .05 gram/mL; and in one embodiment, approximately 8.4 grams of the liposomal amikacin composition per dose is present in the composition of the invention.
• the entire volume of the composition is administered to a subject in need thereof.
• the plianiiaceutical composition provided herein comprises at least one aminoglycoside, at least one phospholipid and a sterol.
• the pharmaceutical composition comprises an aminoglycoside, DPPC and cholesterol.
• the pharmaceutical composition is the composition provided in Table 4, below.
• composition A (pH 6.0-7.0)
• Composition D fpH -6.5)
• composition B (p H 6.0-7.0)
• Composition E (pH ⁇ 6.5)
• composition C fp H 6.0-7.0
• Composition F (pH -6.5)
• lipid to drug ratio is fixed, and as amikacin concentration is increased (and therefore lipid concentration is increased, since the ratio of the two is fixed, for example at -0.7: 1 by weight), the viscosity of the solution also increases, which slows nebulization time.
• the methods described herein comprise administering to a patient in need of treatment of an NTM lung infection, an effective amount of a liposomal aminoglycoside composition via inhalation.
• inhalation delivery is conducted via a nebulizer.
• the nebulizer provides an aerosol mist of the composition for delivery to the lungs of the patient.
• the system provided herein comprises a nebulizer selected from an electronic mesh nebulizer, pneumonic (jet) nebulizer, ultrasonic nebulizer, breath- enhanced nebulizer and breath-actuated nebulizer.
• a nebulizer selected from an electronic mesh nebulizer, pneumonic (jet) nebulizer, ultrasonic nebulizer, breath- enhanced nebulizer and breath-actuated nebulizer.
• the nebulizer is portable.
• the method for treating an NTM infection is carried out via administration of a liposomal com le ed aminoglycoside composition to a patient in need thereof via a nebulizer in once daily dosing sessions.
• the aminoglycoside is amikacin, e.g., amikacin sulfate.
• the lipid component of the liposomes comprises DPPC and cholesterol.
• the nebulizer is one of the nebulizers described in U.S. Patent Application Publication No. 2013/0330400, incorporated by reference herein in its entirety for all purposes.
• a pressurized gas supply is used as the driving force for liquid atomization in a pneumatic nebulizer.
• Compressed gas is delivered, which causes a region of negative pressure.
• the solution to be aerosolized is then delivered into the gas stream and is sheared into a liquid film. This film is unstable and breaks into droplets because of surface tension forces. Smaller particles, i.e., particles with the MMAD and FPF properties described above, can then be formed by placing a baffle in the aerosol stream.
• gas and solution is mixed prior to leaving the exit port (nozzle) and interacting with the baffle. In another embodiment, mixing does not take place until the liquid and gas leave the exit port (nozzle).
• the gas is air, O 2 and/or CO 2 .
• droplet size and output rate can be tailored in a pneumonic nebulizer.
• the gas velocity and/or pharmaceutical composition velocity is modified to achieve the output rate and droplet sizes of the present invention.
• the flow rate of the gas and/or solution can be tailored to achieve the droplet size and output rate of the invention.
• an increase in gas velocity in one embodiment, decreased droplet size.
• the ratio of pharmaceutical composition flow to gas flow is tailored to achieve the droplet size and output rate of the invention.
• an increase in the ratio of liquid to gas flow increases particle size.
• a pneumonic nebulizer output rate is increased by increasing the fill volume in the liquid reservoir. Without wishing to be bound by theory, the increase in output rate may be due to a reduction of dead volume in the nebulizer.
• Nebulization time in one embodiment, is reduced by increasing the flow to power the nebulizer. See, e.g., Clay et al. (1983). Lancet 2, pp. 592-594 and Hess et al. (1996). Chest 110, pp. 498-505.
• a reservoir bag is used to capture aerosol during the nebulization process, and the aerosol is subsequently provided to the subject via inhalation.
• the nebulizer provided herein includes a valved open-vent design. In this embodiment, when the patient inhales through the nebulizer, nebulizer output is increased. During the expiratory phase, a one-way valve diverts patient flow away from the nebulizer chamber.
• the nebulizer provided herein is a continuous nebulizer. In other words, refilling the nebulizer with the pharmaceutical composition while administering a dose is not needed. Rather, the nebulizer has at least an 8 mL capacity or at least a 10 mL capacity.
• the nebulizer provided herein does not use an air compressor and therefore does not generate an air flow.
• aerosol is produced by the aerosol head which enters the mixing chamber of the device. When the patient inhales, air enters the mixing chamber via one-way inhalation valves in the back of the mixing chamber and carries the aerosol through the mouthpiece to the patient. On exhalation, the patient's breath flows through the one-way exhalation valve on the mouthpiece of the device.
• the nebulizer continues to generate aerosol into the mixing chamber which is then drawn in by the subject on the next breath— and this cycle continues unti l the nebulizer medication reservoir is empty.
• the nebulization time of an effective amount of an aminoglycoside composition provided herein is less than 20 minutes, less than 18 minutes, less than 16 minutes or less than 15 minutes. In one embodiment, the nebulization time of an effective amount of an aminoglycoside composition provided herein is less than 15 minutes or less than 13 minutes. In one embodiment, the nebulization time of an effective amount of an aminoglycoside composition provided herein is about 13 minutes.
• composition described herein is administered once daily to a patient in need thereof.
• a patient is treated for an NTM lung infection with one of the methods and/or compositions provided herein.
• the composition comprises a liposomal amikacin composition.
• the composition comprises from about 500 mg to about 600 mg ami kacin, DPPC and cholesterol, and the lipid to aminoglycoside weight ratio of the composition is 0.75 : 1.0 or less, e.g., about 0.7: 1.0 or about 0.5 : 1.0 to about 0.8: 1.0.
• the patient subjected to one of the treatment methods provided herein is a patient that was previously non-responsive to a different NTM treatment.
• the composition administered to the patient in need of treatment is one of the compositions set forth in Table 4, above.
• about 70% to about 100% of the aminoglycoside present in the composition is liposomal complexed.
• the aminoglycoside is an aminoglycoside.
• the aminoglycoside is amikacin.
• the aminoglycoside prior to nebulization, about 80% to about 99%, or about 85% to about 99%, or about 90% to about 99% or about 95%> to about 99%> or about 96% to about 99% of the aminoglycoside present in the composition is liposomal complexed.
• the aminoglycoside is amikacin or tobramycm.
• the aminoglycoside is amikacin.
• prior to nebulization about 98% of the aminoglycoside present in the composition is liposomal complexed.
• the aminoglycoside is amikacin or tobramycin.
• the aminoglycoside is amikacin (e.g., as amikacin sulfate).
• the aminoglycoside agent upon nebulization, about 20%) to about 50% of the liposomal complexed aminoglycoside agent is released, due to shear stress on the liposomes.
• the aminoglycoside agent is an amikacin.
• the aminoglycoside agent upon nebulization, about 25% to about 45%, or about 30% to about 40% of the liposomal complexed aminoglycoside agent is released from the liposomal complex, due to shear stress on the liposomes.
• the aminoglycoside agent is amikacin.
• the amikacin is amikacin sulfate.
• an aerosolized composition Upon nebulization of the composition described herein, i.e., for administration to a patient in need of treatment of an NTM infection, an aerosolized composition is formed, and in one embodiment, the mass median aerodynamic diameter (M MAD) of the aerosolized composition is about 1.0 ⁇ to about 4.2 urn as measured by the Anderson Cascade Impactor (ACI). In one embodiment, the MMAD of the aerosolized composition is about 3.2 um to about 4.2 ⁇ as measured by the ACI. In one embodiment, the MMAD of the aerosolized composition is about 1.0 ⁇ to about 4.9 ⁇ as measured by the Next Generation Impactor (NGI). In a further embodiment, the MMAD of the aerosolized composition is about 4.4 ⁇ to about 4.9 ⁇ as measured by the NGI.
• M MAD mass median aerodynamic diameter
• the fine particle fraction (FPF) of the aerosolized composition in one embodiment, is greater than or equal to about 64%), as measured by the Anderson Cascade Impactor (ACI), or greater than or equal to about 51%, as measured by the Next Generation Impactor (NGI). In one embodiment, embodiment, the FPF of the aerosolized composition is greater than or
• the liposomes in the pharmaceut cal composition leak drug.
• the amount of liposomal complexed aminoglycoside post-nebulization is about 45% to about 85%, or about 50% to about 80% or about 51% to about 77%. These percentages are also referred to herein as "percent associated aminoglycoside post- nebulization.”
• the liposomes comprise an aminoglycoside, e.g., amikacin.
• the percent associated aminoglycoside post-nebulization is from about 60% to about 70%.
• the aminoglycoside is amikacin.
• the percent associated aminoglycoside post-nebulization is about 67%, or about 65% to about 70%.
• the aminoglycoside is amikacin.
• the amikacin is amikacin sulfate.
• the percent associated aminoglycoside post-nebulization is measured by reclaiming the aerosol from the air by condensation in a cold-trap, and the liquid is subsequently assayed for free and encapsulated aminoglycoside (associated aminoglycoside) .
• the methods provided herein are implemented for the treatment or prophylaxis of one or more NTM pulmonary infections in a cystic fibrosis patient.
• the composition administered to the patient in need of treatment is one of the compositions set forth in Table 4, above.
• the patient in need of treatment of the NTM pulmonary infection is a bronchiectasis patient.
• the bronchiectasis is non-Cystic Fibrosis (CF) bronchiectasis.
• the bronchiectasis is associated with CF in a patient in need of treatment.
• the patient in need of treatment of the NTM pulmonary infection is a COPD patient.
• the patient in need of treatment of the NTM pulmonary infection is an asthma patient.
• the composition administered to the patient in need of treatment is one of the compositions set forth in Table 4, above.
• a patient in need of treatment with one of the methods described herein is a Cystic Fibrosis patient, a bronchiectasis patient, a ciliary dyskinesia patient, a chronic smoker, a chronic obstructive pulmonary disorder (COPD) patient, or a patient who has been previously non-responsive to treatment.
• a cystic fibrosis patient is treated for an NTM pulmonary infection with one of the methods provided herein, in yet another embodiment, the patient is a bronchiectasis patient, a COPD patient or an asthma patient.
• the pulmonary NTM infection in one embodiment, is MAC, M. kansasii, M, abscessus, or M. fortidtum. In a further embodiment, the pulmonary NTM infection is a MAC infection.
• a patient subjected to the methods described herein has a co- morbid condition.
• the patient in need of treatment with one of the methods described herein has diabetes, mitral valve disorder (e.g., mitral valve prolapse), acute bronchitis, pulmonary hypertension, pneumonia, asthma, trachea cancer, bronchus cancer, lung cancer, cystic fibrosis, pulmonary fibrosis, a larynx anomaly, a trachea anomaly, a bronchus anomaly, aspergillosis, HIV or bronchiectasis, in addition to the pulmonary NTM infection.
• mitral valve disorder e.g., mitral valve prolapse
• acute bronchitis pulmonary hypertension
• pneumonia asthma
• trachea cancer bronchus cancer
• lung cancer cystic fibrosis
• pulmonary fibrosis a larynx anomaly
• a trachea anomaly a bronchus anomaly
• aspergillosis HIV or
• a patient subjected to one of the NTM methods described herein exhibits an NTM culture conversion to negative during the administration period of the liposomal aminoglycoside composition, or after the administration period has concluded.
• the time to conversion in one embodiment, is about 10 days, or about 20 days or about 30 days or about 40 days, or about 50 days, or about 60 days, or about 70 days, or about 80 days, or about 90 days, or about 100 days or about 110 days.
• the time to conversion is from about 20 days to about 200 days, from about 20 days to about 190 days, from about 20 days to about 180 days, from about 20 days to about 160 days, from about 20 days to about 150 days, from about 20 days to about 140 days, from about 20 days to about 130 days, from about 20 days to about 120 days, from about 20 days to about 110 days, from about 30 days to about 110 days, or from about 30 days to about 100 days.
• the patient experiences an improvement in lung function for at least 15 days after the administration period ends, as compared to the FEV. of the patient prior to treatment.
• the patient may experience an increase in FEVi, an increase in blood oxygen saturation, or both.
• the patient has an FEVj (after the admin stration period or treatment cycle) that is increased by at least 5% over the ⁇ EV ⁇ prior to the administration period.
• FEVj is increased by 5 to 50 % over the FEVi prior to the administration period.
• FEVi is increased by 25 to 500 mL over FEV j prior to the administration period
• blood oxygen saturation is increased by at least 1% over oxygen saturation prior to the administration period.
• the 6-min te walk test (6 WT) is used to assess the effectiveness of the treatment methods provided herein.
• the 6MWT is used for the objective evaluation of functional exercise capacity and is a practical, simple test that measures the distance that a patient can walk in a period of 6 minutes ⁇ see American Thoracic Society. (2002). Am J Respir Crit Care Med, 166, pp. 1 1 1 -117, incorporated by reference herein in its entirety for ail purposes).
• a patient subjected to one of the NTM methods described herein exhibits an increased number of meters walked in the 6MWT, as compared to prior to undergoing the treatment method.
• the increased number of meters walked in the 6MWT in one embodiment, is about 5 meters, about 10 meters, about 15 meters, about 20 meters, about 25 meters, about 30 meters, about 35 meters, about 40 meters, about 45 meters, or about 50 meters.
• the increased number of meters walked in the 6MWT is at least about 5 meters, at least about 10 meters, at least about 15 meters, at least about 20 meters, at least about 25 meters, at least about 30 meters, at least about 35 meters, at least about 40 meters, at least about 45 meters, or at least about 50 meters.
• the increased number of meters walked in the 6MWT is from about 5 meters to about 50 meters, or from about 5 meters to about 40 meters, or from about 5 meters to about 30 meters or from about 5 meters to about 25 meters.
• a patient subjected to one of the NTM methods described herein exhibits a greater number of meters walked in the 6MWT, as compared to a patient undergoing a non-liposomal aminoglycoside treatment.
• the greater number of meters walked in the 6MWT, as compared to a patient undergoing a non-liposomal aminoglycoside treatment in one embodiment, is about 5 meters, about 10 meters, about 15 meters, about 20 meters, about 25 meters, about 30 meters, about 35 meters, about 40 meters, about 45 meters, about 50 meters, about 60 meters, about 70 meters or about 80 meters.
• the greater number of meters walked in the 6MWT is at least about 5 meters, at least about 10 meters, at least about 15 meters, at least about 20 meters, at least about 25 meters, at least about 30 meters, at least about 35 meters, at least about 40 meters, at least about 45 meters, or at least about 50 meters. In yet another embodiment, the greater number of meters walked in the 6MWT is from about 5 meters to about 80 meters, or from about 5 meters to about 70 meters, or from about 5 meters to about 60 meters or from about 5 meters to about 50 meters.
• the liposomal aminoglycoside composition provided herein is administered to a patient in need of treatment of an NTM kmg disease with an additional therapy.
• the liposomal aminoglycoside composition provided herein is administered to a patient in need of treatment of an NTM lung disease with one or more additional therapeutic agents.
• the one or more additional therapeutics agents in one embodiment is administered orally.
• the one or more additional therapeutics agents in one embodiment is administered intravenously.
• the one or more additional therapeutics agents in one embodiment is administered via inhalation.
• the one or more additional therapeutic agents in one embodiment is a macrolide antibiotic.
• the macrolide antibiotic is azithromycin, clarithromycin, erythromycin, carbornycin A, josamycin, kitamycin, midecamycm, oleandomycin, solithromycin, spiramycin, troleandomycin, tylosin, roxithromycin, or a combination thereof.
• the macrolide antibiotic is administered orally.
• the one or more additional therapeutic agents is the macrolide antibiotic azithromycin, clarithromycin, erythromycin, or a combination thereof.
• the macrolide antibiotic is administered orally.
• the liposomal aminoglycoside composition provided herein is administered to a patient in need of treatment of an NTM lung disease with one or more additional therapeutic agents, and the one or more additional therapeutic agents is a rifamycin compound.
• the rifamycin is rifampin.
• the rifamycin is rifabutin, rifapentine, rifaximin, or a combination thereof.
• the one or more additional therapeutic agents is a quinolone.
• the quinolone is a fluoroquinolone.
• the quinolone is ciprofloxacin, levofloxacin, gatifloxacin, enoxacin, levofloxacin, ofloxacin, moxifloxaein, trovafloxacin, or a combination thereof.
• a second therapeutic agent is administered to the patient in need of NTM treatment, and the second therapeutic agent is a second aminoglycoside.
• the second aminoglycoside is amikacin, apramycin, arbekacin, astromicin, j l bekanamycin, boholmycin, brulamycin, capreomycin, dibekacin, dactimicin, etimicin, frarnycetiri, gentarnicm, HI 07, hygromycin, hygromycin B, mosamycrn, K-4619, isepamicin, KA-5685, kanamycin, neomycin, netilmicin, paromomycin, plazomicin, ribostamycin, sisomicm, rhodestreptomycm, sorbistin, spectinornycin, sporaricm, streptomycin, tobramycin, ver
• the liposomal aminoglycoside composition provided herein is administered to a patient in need of treatment of an NTM lung disease with one or more additional therapeutic agents, and the one or more additional therapeutic agents is ethambutol, isorsiazid, cefoxitin or imipenem.
• LAI also referred to herein as “ArikayceTM” or “ARIKAYCETM”
• DB randomized, double-blind
• the LAI composition had the following components:
• ⁇ 2 ⁇ Eligible NTM patients on a stable drag regimen were stratified based on presence or absence of cystic fibrosis (CF), and Mycobacterium avium complex (MAC) versus Mycobacterium abscessus (M. abscessus) lung disease, and randomized 1 : 1 to receive either once daily 590 mg LAI or placebo via eFlow® nebulizer system (PARI Pharnia GmbH) for 84 days added to their ongoing stable drug regimen.
• Figure 3 shows the number of patients in each group (randomized per strata). Patients were eligible for enrollment if they had pulmonary NTM infection refractory to American Thoracic Society / Infectious Disease Society of America (ATS/IDSA) guideline-based therapy for >6 months prior to screening.
• ATS/IDSA Infectious Disease Society of America
• the sample population enrolled in the mlTT study exhibited the following; (1) comorbid lung disease, with 17 of the patients having cystic fibrosis; (2) a mean age of 59 years, including the younger cystic fibrosis patients; (3) lung abnormalities including 68 patients with cavitary lesions, and 21 patients with nodular disease which further includes minimal cavitary disease; (4) a mean body mass index (BMI) of 21.98, whereas comparable CDC data collected from between 2007 and 2010 reveals U.S average BMI of adult males to be 28.6 and adult females to be 28.7; and (5) an average baseline of -441 m for all patients, with bot arms having approximately the same mean baseline six-minute walk distance.
• BMI body mass index
• Figure 4 is a graph showing the mean change from baseline on the full semi quantitative scale for mycobacterial culture (mlTT population) as a function of study day in both the double-blind phase and the open-label phase of the study. As shown in the figure, patients treated with LAI showed at least a one-step reduction in the treatment arm versus the placebo arm in the double-blind phase.
• the proportion of patients with negative sputum cultures for NTM in each subgroup by treatment arm at Day 84 and Day 168 (mJTT population) are summarized in Tables 6-8. At Day 84, statistically significant between-group differences in patients achieving negative sputum cultures for NTM, in favor of LAI vs.
• LAI an inhaled amikacin composition
• Table 6 Proportion of Patients with negative sputum cultures for NTM in each
• CF cystic fibrosis
• LA! iiposomai amikacin for inhalation
• MAB Mycobacterium avium complex
• m!TT modified intent-to-treat
• NTM nontubercu!ous mycobacteria
• NA not available.
• Missing values are excluded under the assumption of missing at random, for which missing baseline or post-baseline values are excluded but ail non-missing data are included (ie, exclusion is not at subject-level but, rather, at time point-level).
• Non-Caucasian 0/0 0/3 NA 0/0 0/3 NA
• CF cystic fibrosis
• LAI iiposomai amikacin for inhalation
• MAC Mycobacterium avium complex
• mITT modified intent-to-treat
• NA not available
• Missing values are excluded under the assumption of missing at random, for which missing baseline or post-baseline values are excluded but ail non-missing data are included (le, exclusion is not at subject-level but, rather, at time point-level).
• CF cystic fibrosis
• LAi liposomal amikacin for inhalation
• MAB Mycobacterium abscessus: MiTT, modified intent-to-treat
• NA not available.
• Missing values are excluded under the assumption of missing at random, for which missing baseline or post-baseline values are excluded but ail non-missing data are included (le, exclusion is not at subject-level but, rather, at time point-level).
• the six-minute walk test assessed the impact of LAi on overall physical function or capacity. Results for the 6MWT endpoint (change from baseline from Day 1 to Day 84 at end of double blind study) are provided in Figure 7 and Figure 8.
• sample population enrolled in the mITT study exhibited the following, prior to day 168, with regard to culture conversion, measured as three consecutive negative sputum cultures: (1) a total of 16 patients demonstrated culture conversion, all of which were non- cystic fibrosis; (2) 15 patients had MAC and 1 had M.
• Example 2 Study of Liposomal Amikacin for Inhalation (LAI) in Patients with Non-CF M. avium complex (MAC) Lung Infection
• LAI (also referred to herein as “ArikayceTM” or “A IKAYCETM”) is a sustained- release lipid composition of amikacin in development for treatment of patients with recalcitrant NTM lung disease, in this study, the efficacy, safety, and tolerability of LAI is assessed in non-Cystic Fibrosis patients having M. avium complex (MAC) lung infection.
• Figure 9 is a flow chart showing the study design.
• the LAI composition has the following components:
• Table 10 provides the inclusion criteria for the study.
• Patients are randomized 2: 1. into two groups: (i) 590 mg LAI - ⁇ - background therapy and (ii) background therapy only). Each patient group is subjected to daily dosing for 8 months. Primary culture conversion is assessed at 6 months. 6MWT is also carried out for each patient at 6 months.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Dispersion Chemistry (AREA)
• Pulmonology (AREA)
• Otolaryngology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Dermatology (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Biophysics (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (36)

Applications Claiming Priority (8)

Related Child Applications (2)

Publications (1)

Family

ID=54480776

Family Applications (1)

Country Status (23)

Cited By (14)

Families Citing this family (15)

Citations (3)

Family Cites Families (364)

• 2015
  • 2015-05-15 EP EP18203799.4A patent/EP3466432B1/en active Active
  • 2015-05-15 KR KR1020167035068A patent/KR102447412B1/ko active Active
  • 2015-05-15 EP EP15791964.8A patent/EP3142643B1/en active Active
  • 2015-05-15 SM SM20200516T patent/SMT202000516T1/it unknown
  • 2015-05-15 SI SI201531365T patent/SI3466432T1/sl unknown
  • 2015-05-15 MX MX2020010726A patent/MX384843B/es unknown
  • 2015-05-15 SI SI201530934T patent/SI3142643T1/sl unknown
  • 2015-05-15 RS RS20201143A patent/RS60827B1/sr unknown
  • 2015-05-15 LT LT15791964T patent/LT3142643T/lt unknown
  • 2015-05-15 DK DK15791964.8T patent/DK3142643T3/da active
  • 2015-05-15 PT PT182037994T patent/PT3466432T/pt unknown
  • 2015-05-15 CN CN201580038417.XA patent/CN106535877A/zh active Pending
  • 2015-05-15 PT PT157919648T patent/PT3142643T/pt unknown
  • 2015-05-15 ES ES20182665T patent/ES2926985T3/es active Active
  • 2015-05-15 CA CA2949078A patent/CA2949078C/en active Active
  • 2015-05-15 MX MX2016014921A patent/MX376012B/es active IP Right Grant
  • 2015-05-15 EP EP24163449.2A patent/EP4393491A3/en active Pending
  • 2015-05-15 PL PL15791964T patent/PL3142643T3/pl unknown
  • 2015-05-15 ES ES22182229T patent/ES2981634T3/es active Active
  • 2015-05-15 BR BR112016026699-4A patent/BR112016026699B1/pt not_active IP Right Cessation
  • 2015-05-15 EP EP20182665.8A patent/EP3766501B1/en active Active
  • 2015-05-15 US US14/713,926 patent/US9895385B2/en active Active
  • 2015-05-15 LT LTEP18203799.4T patent/LT3466432T/lt unknown
  • 2015-05-15 ES ES18203799T patent/ES2820226T3/es active Active
  • 2015-05-15 HR HRP20191805TT patent/HRP20191805T1/hr unknown
  • 2015-05-15 EP EP22182229.9A patent/EP4122470B1/en active Active
  • 2015-05-15 PL PL18203799T patent/PL3466432T3/pl unknown
  • 2015-05-15 KR KR1020237001082A patent/KR102657132B1/ko active Active
  • 2015-05-15 US US15/311,488 patent/US10238675B2/en active Active
  • 2015-05-15 JP JP2017512871A patent/JP6646653B2/ja active Active
  • 2015-05-15 DK DK18203799.4T patent/DK3466432T3/da active
  • 2015-05-15 NZ NZ726256A patent/NZ726256A/en unknown
  • 2015-05-15 ES ES15791964T patent/ES2755941T3/es active Active
  • 2015-05-15 KR KR1020247003025A patent/KR20240018675A/ko not_active Ceased
  • 2015-05-15 HU HUE18203799A patent/HUE051440T2/hu unknown
  • 2015-05-15 ME MEP-2019-271A patent/ME03536B/me unknown
  • 2015-05-15 AU AU2015258947A patent/AU2015258947B2/en active Active
  • 2015-05-15 WO PCT/US2015/031079 patent/WO2015175939A1/en not_active Ceased
  • 2015-05-15 KR KR1020227032656A patent/KR102489036B1/ko active Active
• 2018
  • 2018-01-09 US US15/866,143 patent/US20180185401A1/en not_active Abandoned
  • 2018-06-13 US US16/007,075 patent/US10251900B2/en active Active
• 2019
  • 2019-01-17 US US16/250,476 patent/US10398719B2/en active Active
  • 2019-01-31 US US16/263,648 patent/US10751355B2/en active Active
  • 2019-07-18 US US16/515,303 patent/US10588918B2/en active Active
  • 2019-10-04 CY CY20191101044T patent/CY1122129T1/el unknown
• 2020
  • 2020-01-10 JP JP2020002791A patent/JP6892529B2/ja active Active
  • 2020-01-31 US US16/778,506 patent/US10828314B2/en active Active
  • 2020-07-07 AU AU2020204530A patent/AU2020204530B2/en active Active
  • 2020-07-15 US US16/930,134 patent/US11446318B2/en active Active
  • 2020-09-24 US US17/031,744 patent/US11395830B2/en active Active
  • 2020-10-06 CY CY20201100936T patent/CY1123411T1/el unknown
• 2021
  • 2021-05-27 JP JP2021089011A patent/JP7212717B2/ja active Active
• 2022
  • 2022-06-21 US US17/845,688 patent/US12168021B2/en active Active
  • 2022-08-08 US US17/883,491 patent/US12016873B2/en active Active
  • 2022-10-07 US US17/962,115 patent/US12168022B2/en active Active
• 2023
  • 2023-01-13 JP JP2023003885A patent/JP7686017B2/ja active Active
• 2024
  • 2024-05-13 US US18/662,516 patent/US12377114B2/en active Active
  • 2024-11-07 US US18/940,508 patent/US20250057863A1/en active Pending
• 2025
  • 2025-05-20 JP JP2025084405A patent/JP2025122086A/ja active Pending
  • 2025-07-02 US US19/258,643 patent/US20250325574A1/en active Pending